Filtered By:
Source: Cancer Research
Therapy: Cancer Therapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 42 results found since Jan 2013.
Abstract 707: Tumor-targeted delivery of siRNA using stabilized calcium phosphate nanoparticles based on bio-inspired hyaluronic acid conjugate
Conclusion Considering its biocompatibility, transfection efficacy, and tumor targeting capability, this stabilized organic-inorganic hybrid gene delivery platform should be considered a promising candidate carrier for systemic siRNA delivery and targeted cancer therapy.
Citation Format: Min Sang Lee, Jung Eun Lee, Eunkyoung Byun, Nak Won Kim, Haeshin Lee, Ji Hoon Jeong. Tumor-targeted delivery of siRNA using stabilized calcium phosphate nanoparticles based on bio-inspired hyaluronic acid conjugate. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Di...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Lee, M. S., Lee, J. E., Byun, E., Kim, N. W., Lee, H., Jeong, J. H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract LB-103: L1CAM-targeted delivery of siRNA using elastin-like polypeptide (ELP) nanoparticles inhibits the growth of human tumors implanted in mice
Small interfering RNA (siRNA) drugs provide ideal means for perturbing intracellular oncogenic targets. However, specific delivery of siRNA to tumors has proven to be difficult. An ELP was engineered with an N-terminal region that binds to L1 cell adhesion molecule (L1CAM), and a C-terminal region that binds siRNA. Upon binding of siRNA, the L1CAM targeted ELP (ELP-L) spontaneously assembled into a spherical nanocomplex with the siRNA protected within, and the CAM-binding region protruding from the surface. These nanoparticles were used to deliver siRNA to SKOV3 tumors formed following surgical implantation of the cells in...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Primiano, T., Chang, B.-D., Heidel, J. D. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract P2-07-04: Treatment of metastatic breast cancer using two nanoparticles combined with siRNA targeting Twist1 to inhibit EMT
Breast cancer is the 2nd leading cause of cancer related deaths among women in the US with over 240,000 diagnoses and 40,000 deaths expected in 2014. Among the more serious and deadly forms of breast cancer are the Triple Negative Breast Cancers (TNBC) (ER-, PR-, HER2-). Mortality rates among patients rise dramatically when these cancers spread beyond the primary tumor site. Therefore reduction of tumor cell dispersion is a key component to minimizing mortality rates. Epithelial-Mesenchymal Transition (EMT) is the process by which cancer cells downregulate proteins associated with cell to cell adhesion (e.g. E-cadherin) re...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Finlay, J. B., Roberts, C. M., Lowe, G., Peng, L., Zink, J. I., Tamanoi, F., Glackin, C. A. Tags: Poster Session Abstracts Source Type: research
Abstract LB-102: Layer-by-layer engineering of upconversion nanoparticle based siRNA and miRNA delivery system for cancer therapy
Conclusions: In this proof-of-concept study, a layer-by-layer engineered UCNP based siRNA and miRNA delivery system was successfully developed. Our novel delivery system opens up preparation of advanced UCNP based photoresponsive delivery systems that allow remote, precise, and trackable control over therapeutic payload (e.g., drug, gene) release for better cancer theranostics.Citation Format: Lin Min, YAN GAO, Francis J. Hornicek, Mansoor M. Amiji, Zhenfeng Duan. Layer-by-layer engineering of upconversion nanoparticle based siRNA and miRNA delivery system for cancer therapy. [abstract]. In: Proceedings of the 106th Annual...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Min, L., GAO, Y., Hornicek, F. J., Amiji, M. M., Duan, Z. Tags: Cancer Chemistry Source Type: research
Abstract 5416: Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers
Successful siRNA based therapy has the potential to revolutionize cancer therapy by mediating the silencing of any gene deemed important for disease progression. However, unprotected siRNA has a short half-life in blood and lacks the ability to selectively identify target cells. Our group is developing an effective siRNA based nanoparticle platform that overcomes these shortcomings by utilizing a mesoporous silica nanoparticle electrostatically loaded with siRNA and conjugated with an antibody for target homing. The human epidermal growth receptor type 2 (HER2) is a highly validated therapeutic target in breast cancer due ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Goodyear, S. M. Tags: Cancer Chemistry Source Type: research
Abstract 718: Systemic delivery of therapeutic siRNA by multifunctional mesoporous silica-based nanocarrier inhibits lung cancer growth and metastasis
In this study, we developed a novel siRNA delivery vector based on our magnetic mesoporous silica nanoparticles (M-MSNs) platform. This nanocarrier was constructed by loading siRNAs into the mesopores of M-MSNs, followed by polyethylenimine (PEI) capping, PEGylation and fusogenic peptide KALA modification. The resultant functionalized delivery system exhibited prolonged half-life in bloodstream, enhanced cell membrane translocation and endosomal escapablity, and favorable tissue biocompatibility and biosafety. Systemic application of vascular endothelial growth factor (VEGF) siRNA via this nanocarrier resulted in remarkabl...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Chen, Y., Gu, H., Xia, W. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 1455: Therapeutic synergy between novel tumor suppressor miR-520d-3p and EphA2-targeting siRNA in ovarian cancer
This study addresses a new concept of RNA inhibition therapy by combining miRNA and siRNA to target oncogenic pathways altered in ovarian cancer.
Citation Format: Maitri Shah, Gabriel Berestein Lopez, Anil Sood, George Calin. Therapeutic synergy between novel tumor suppressor miR-520d-3p and EphA2-targeting siRNA in ovarian cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1455. doi:10.1158/1538-7445.AM2014-1455
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Shah, M., Lopez, G. B., Sood, A., Calin, G. Tags: Molecular and Cellular Biology Source Type: research
Abstract 2603: Specific growth suppression of wild-type p53 tumor cells by DNA-modified siRNA sequences targeting MDM2
Conclusions: Our 2 newly selected dsRDC-modified siRNAs had high knockdown activity and less nonspecific cytotoxicity. Thus, they represent potent therapeutic agents against cancers carrying wt p53 with MDM2 overexpression.
Citation Format: Mitsuaki Hirose, Kenji Yamato, Rie Saito, Takunori Ueno, Sachiko Hirai, Hideo Suzuki, Shinji Endo, Ichinosuke Hyodo. Specific growth suppression of wild-type p53 tumor cells by DNA-modified siRNA sequences targeting MDM2. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer R...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Hirose, M., Yamato, K., Saito, R., Ueno, T., Hirai, S., Suzuki, H., Endo, S., Hyodo, I. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5418: Tumor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and cell migration
Conclusions. Tumor-targeted nanoparticle delivery of HuR-RNAi in lung cancer cells selectively inhibited HuR and HuR-regulated oncoproteins resulting in diminished cell proliferation and cell migration in vitro.
Acknowledgement. This study was funded by a grant (R01CA167516-01) from the National Cancer Institute.
Citation Format: Ranganayaki Muralidharan, Anish Babu, Kanthesh Basalingappa, Anupama Munshi, Rajagopal Ramesh. Tumor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and cell migration. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Canc...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Muralidharan, R., Babu, A., Basalingappa, K., Munshi, A., Ramesh, R. Tags: Cancer Chemistry Source Type: research
Abstract 287: Specific delivery of immunostimulatory RNA via nanoparticles blocks growth of primary and disseminated ovarian tumors
One important mechanism of immune evasion is the accumulation of tumor-infiltrating regulatory T cells creating an immunosuppressive microenvironment in situ. Many new therapies target immune checkpoint receptors, CTLA-4 and PD-1, on immunosuppressive T-cells to reverse tumor immune evasion. Small interfering RNAs (siRNAs) are double stranded, sequence-specific inhibitors of gene expression. The paradigm for using siRNA to block cancer is to target mRNA sequences of oncogenes. Several limitations have suppressed the use of siRNA in human cancer therapy, such as off-target effects and lack of tumor-specific delivery. Additi...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Primiano, T., Chang, B.-i. Tags: Immunology Source Type: research
Abstract 4054: Elongation factor-2 kinase (eEF-2K) promotes cell invasion and epithelial mesenchymal transition through regulation of TG2-mediated signaling in human pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) accounts for the majority of pancreatic cancer (PaCa) cases and is currently uncurable with poor prognosis/survival rates (∼4% 5-year survival). The extensive local tumor invasion, early metastasis/systemic dissemination and resistance to existing cancer therapies are the major characteristics of PaCa and the impediment to effective cure of this disease. Although PaCa has a well-defined spectrum of highly oncogenic lesions (e.g, mutations in K-RAS, p53, p16ink4a, and SMAD4/DPC4), effective therapies have not yet been developed. Therefore, novel molecular targets-based therapeutic s...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Ashour, A. A., Alpay, S. N., Gurbuz, N., Abdel-Aziz, A.-A. H., Mansour, A. M., Ozpolat, B. Tags: Tumor Biology Source Type: research
Abstract 731: SRI-28731, a highly potent and selective MAP4K4 (HGK) inhibitor for cancer therapy
MAP4K4, a Ser/Thr kinase, was identified as an important pro-migratory kinase in an siRNA screen, targeting 5,234 human genes for modulators of tumor cell motility. MAP4K4 siRNA potently suppressed cell invasion and migration of multiple cancer cell lines, indicating a broad role in cell motility. There are no drugs in the clinic that are known to specifically target MAP4K4 for cancer therapy.
We have successfully developed an orally active, highly effective and selective MAP4K4 inhibitor (SRI-28731) with potent in vitro and in vivo anticancer activity. SRI-28731 is more potent than Paclitaxel (Taxol) against most of the b...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Chang, C.-T., Park, J., Zhou, W., Liu, X., Sato, B., Dinh, D., Furimsky, A., Beviglia, L., Sambucetti, L., Jong, L. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 4870: Proteomics of phyllodes tumor revealed that decorin increase in the extracellular matrix by periostin deficiency decreased cancer cell motility and invasion
The ability of cancer cells to metastasize is dependent on the interactions of their cell surface molecules with microenvironment. However the tumor microenvironment, especially cancer-associated stroma, is poorly understood. To search for proteins which are present in the stroma, we investigated the phyllodes tumor, which contains breast stromal tissue, specific expression proteins compared with normal tissue by using iTRAQ-based quantitative proteomic approach. Periostin and versican core protein were up-regulated in phyllodes tumor. Decorin, mimecan, hemoglobin subunit alpha, hemoglobin subunit beta and ketatin, type1 c...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Ishiba, T., Nakanishi, A., Sato, T., Nakagawa, T., Nagahara, M., Oono, R., Uetake, H., Sugihara, K., Miki, Y. Tags: Tumor Biology Source Type: research
Abstract 5203: Long non-coding RNA H19 as a novel therapeutic target for pancreatic cancer
Long non-coding RNAs (lncRNAs), non-protein coding transcripts longer than 200 nucleotides, have been recently reported to play important roles in carcinogenesis and cancer metastasis through epigenetic regulation. In the present study, we examined the expression levels and roles of lncRNA in pancreatic cancer to elucidate whether lncRNA could be a novel candidate for pancreatic cancer therapy. First, we injected PANC-1 and PK-45H, pancreatic ductal adenocarcinoma cells into the spleens of NOD/Shi-scid, IL-2Rγnull (NOG) mice, and then established novel cell lines from liver and lung metastatic nodules. Microarray analysis...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yoshimura, H., Matsuda, Y., Suzuki, T., Naito, Z., Ishiwata, T. Tags: Molecular and Cellular Biology Source Type: research
Abstract B57: RNAi Nanotechnology for Cancer Target Validation and Therapy
RNA interference (RNAi) represents a promising strategy for identification and validation of putative therapeutic targets, and for treatment of a myriad of important human diseases including cancer. The ubiquitous application of RNAi in cancer research and therapy is nevertheless hindered by the challenge of effective systemic in vivo delivery of RNAi agents (e.g., siRNA) to solid tumors, which requires overcoming of multiple physiological barriers, such as enzymatic degradation, rapid elimination by renal excretion or by the mononuclear phagocyte system (MPS), poor tumor penetration, and insufficient cellular uptake and e...
Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jinjun Shi Tags: Tumor Immunology/Immunotherapy Source Type: research
